RxDoctor Payments Data

Shafeeq Ladha, MD

Neuromuscular Medicine · Phoenix, AZNPI 1417931767

Payments from drug & device makers

$2,473,564in general payments, 2019–2025

Across 635 payments — averaging $3895.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1.1M
  • Sanofi$688K
  • Mitsubishi Tanabe Pharma Development America, Inc.$163K
  • Genentech USA, Inc.$136K
  • Spark Therapeutics, Inc.$104K
  • Genentech, Inc.$56K
  • plus $227K from 18 others
$16,065in research payments, 2019–2025

Across 45 payments — averaging $357.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$14K
  • Biogen$2K
  • Spark Therapeutics, Inc.$75

What the payments were for

  • Consulting fees$125,15523%
  • Speaking & faculty fees$348,89265%
  • Travel & lodging$57,02511%
  • Food & beverage$9,0052%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$914,154
Medicare patients
296
Services billed
12,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone392$5,582,774
EvrysdiRisdiplam59$1,828,816
FirdapseAmifampridine Phosphate12$340,450
RelyvrioSod Phenylbutyrat/Taurursodiol26$310,975
Riluzole121$29,005
Azathioprine19$2,820
Mycophenolate Mofetil17$861
Glycopyrrolate21$844
Baclofen46$793
Prednisone83$556
Clonazepam41$156
Escitalopram Oxalate22$116
Fluoxetine Hcl11$70
Trazodone Hcl16$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$136,163$1,828,81659 claims
Amylyx Pharmaceuticals, Inc.Relyvrio$14,587$310,97526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Phoenix

Where these figures come from

Is this you, or does something look wrong? →